Outcomes4Me Partners with Invitae to Offer Genetic Testing to Breast Cancer Patients

Rhea-AI Summary

Outcomes4Me Inc. has partnered with Invitae Corporation (NYSE: NVTA) to enhance education and access to genetic testing for breast cancer patients. This collaboration integrates Invitae's clinical-grade genetic testing with Outcomes4Me's innovative mobile app, revolutionizing patient support and treatment options. Nearly 46% of patients eligible for testing were unaware of their options. The app facilitates genetic counseling and testing integration, empowering patients to make informed decisions. This partnership aims to enhance personalized care and improve health outcomes by providing accessible resources to cancer patients.

Positive

• Partnership with Invitae enhances patient access to genetic testing.
• Approximately 46% of eligible patients unaware of genetic testing options indicates a significant market opportunity.
• Outcomes4Me app includes genetic counseling and testing, integrating with comprehensive cancer care.

Negative

• The need for genetic testing awareness suggests existing gaps in patient knowledge.
• Potential dependency on this partnership for better patient outcomes could pose risks if unmet.

Collaboration Will Educate and Empower Patients to Pursue Needed Personalized Care After a Cancer Diagnosis

BOSTON--(BUSINESS WIRE)-- Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to expand education and access to genetic testing to breast cancer patients and survivors. The collaboration leverages the strengths of Invitae, which supplies clinical grade genetic testing, and Outcomes4Me’s 360-degree, validated and evidence-based cancer support and treatment options via its free and easy-to-use app. Initially and currently available in the United States, patients can now receive genetic counseling through Invitae’s partnership with Genome Medical, get testing, and upload their results within the Outcomes4Me app.

There is a misconception that genetic testing is only useful as a preventative tool prior to a cancer diagnosis. According to Outcomes4Me patient data, almost half of users (46 percent) who qualified for testing (based on NCCN Guidelines®) did not receive testing or did not know if they had received testing. However, genetic testing can provide insights that can help inform and refine precision therapy use and clinical treatment trial enrollment. In addition, genetic testing results can be used to help prevent recurrence and reduce incidence of other inherited cancers.

A cancer diagnosis is often overwhelming for patients and their families. Outcomes4Me demystifies cancer by providing the most up-to-date and validated research, support, and treatment options, all grounded in science and data and curated according to the patient’s specific diagnosis. Outcomes4Me partners with the researchers, doctors, and academics that set the rigorous standards of cancer care for all treatment providers, including the National Comprehensive Care Network® (NCCN®), Vanderbilt-Ingram Cancer Center (VICC) and Massachusetts General Hospital (MGH). The collaboration with Invitae expands access to genetic testing, a vitally important tool in the patient’s cancer care arsenal.

“Outcomes4Me is an indispensable platform for patients with breast cancer, giving them the personalized knowledge and access to timely new trials and targeted therapies that could lead to better health outcomes,” said Ed Esplin, M.D., Ph.D., FACMG, FACP, Clinical Geneticist at Invitae. “By providing access to our comprehensive genetic testing and counseling services, Outcomes4Me is adding a valuable resource that will empower patients to advance their knowledge, understanding, and therefore, self-advocacy during treatment and survivorship.”

Unlike popular direct-to-consumer genetic testing services, which test for a few specific genetic variants for certain genes, Invitae provides state-of-the-art clinical grade next-generation sequencing-based (NGS) genetic testing that comprehensively analyses more than 80 genes, including all known mutations of the important BRCA1/BRCA2 genes. This comprehensive approach, combined with associated genetic counseling, not only provides insights for cancer patients, but also for family members who may be at risk.

“Our collaboration with Invitae reinforces Outcomes4Me’s mission to give patients back control,” said Maya R. Said, Sc. D., Founder and CEO of Outcomes4Me. “Because of this work with Invitae, our valued community now has rare direct access to a much-needed testing service. Outcomes4Me will proudly continue to democratize the best in cancer treatment, research, and support by removing barriers and bias in information flow.”

The Outcomes4Me app is available free to users on both the App Store and Google Play.

About Invitae

Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at www.invitae.com.

About Outcomes4Me

Outcomes4Me is on a mission to improve health outcomes by empowering patients with understandable, relevant and evidence-based information. Outcomes4Me has developed a platform for shared decision-making between patients and providers. The platform harnesses regulatory-grade, real-world data and patient experiences generating deeper insights and better outcomes to improve care and accelerate research. The Outcomes4Me mobile app enables cancer patients to make decisions and take control of their care based on information that is personalized to their specific condition, including finding treatment options, matching to clinical trials, and tracking and managing symptoms. Based in Boston, Massachusetts, Outcomes4Me, a woman-led company, comprises seasoned healthcare, oncology, pharmaceutical, consumer and technology veterans. For more information, visit www.outcomes4me.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005643/en/

Media Contact: Joshua Milne, pr@outcomes4me.com, 617-501-1620

Source: Outcomes4Me Inc.

FAQ

What is the significance of the partnership between Outcomes4Me and Invitae Corporation (NYSE: NVTA)?

The partnership aims to enhance education and access to genetic testing for breast cancer patients, integrating advanced genetic testing with personalized care.

How does the collaboration between Outcomes4Me and Invitae benefit cancer patients?

It provides patients with access to genetic counseling and testing services through a user-friendly mobile app, empowering better health decisions.

What percentage of patients eligible for genetic testing were unaware of their options according to the Outcomes4Me data?

According to Outcomes4Me, nearly 46% of eligible patients did not receive genetic testing or were unaware of whether they received it.

What features does the Outcomes4Me app offer to cancer patients?

The app facilitates access to genetic counseling, testing, and provides evidence-based cancer support and treatment options tailored to individual needs.

How does Invitae's genetic testing differ from direct-to-consumer services?

Invitae offers comprehensive clinical-grade genetic testing analyzing more than 80 genes, including BRCA1/BRCA2 mutations, unlike many direct-to-consumer services which may focus on limited variants.